A precision, computer-vision measurement system for the early diagnosis of schizophrenia

Project Information

Gazelab

Grant agreement ID: 685063

DOI 10.3030/685063

Closed project

EC signature date 23 June 2015

Start date 1 May 2015

End date 31 October 2015

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

BCNINNOVA TECHNOLOGICAL EVOLUTION SL
Spain

Objective

Strabismus, the disorder in which the eyes do not line up in the same direction, affects around 10.5 million Europeans.
Around 30% of strabismus surgeries need to be repeated due to inaccurate ocular measurements. At any point in time,
about 10% of the adult population will report having some type of mental or behavioral disorder, such as schizophrenia.
These two seemingly unrelated pathologies have one thing in common: they can be detected using ocular biomarkers. The
goal of this project is to validate ocular biomarkers for a range of pathologies, including ophthalmological, neurological,
mental, and endocrinological disorders. The clinical validations will be conducted using GazeLab, a computer vision-based
system that accurately measures ocular motility and pupillary dynamics. Our innovative all-in-one solution can be deployed
as a point-of-care diagnostic tool, leading to quicker and more effective treatments for a variety of disorders.
Strabismus patients are the first beneficiaries of our technology and are currently driving demand for GazeLab within the
ophthalmological sector. As we validate more biomarkers for ocular pathologies we will add value to our product for
ophthalmologists. Mental health professionals overwhelmingly diagnose subjectively, and can miss physiological symptoms
that ocular biomarkers can detect.
The goal of this SME Instrument phase 1 project is to determine if GazeLab represents a scalable, repeatable business model to help diagnose a variety of pathologies. If this is the case, we will proceed to request funding through phase 2. In phase 2 we aim to conduct large-scale validations necessary for GazeLab to be approved for the defined applications in a clinical setting. Our target markets include ophthalmologists, neuro-ophthalmologists, neurologists and psychiatrists. Our ultimate goal is to position GazeLab as the industry standard for precision ocular motility measurement and pupillography throughout a range of clinical specialties

Fields of science

• medical and health sciences › clinical medicine › ophthalmology › strabismus

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2015

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

BCNINNOVA TECHNOLOGICAL EVOLUTION SL

• Net EU contribution: € 50 000,00
• Address: CALLE COVADONGA 378 4 1 A ; 08203 Barcelona ; Spain
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Este › Cataluña › Barcelona
• Region: Este › Cataluña › Barcelona
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00